These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 35428910)

  • 61. Successful treatment of BRAF/MEK inhibitor-resistant advanced cutaneous melanoma with nivolumab plus ipilimumab combination therapy followed by intensity-modulated radiotherapy.
    Okuma T; Furudate S; Kambayashi Y; Hashimoto A; Aiba S; Fujimura T
    J Dermatol; 2021 Sep; 48(9):1419-1422. PubMed ID: 34002878
    [TBL] [Abstract][Full Text] [Related]  

  • 62. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma.
    Frederick DT; Piris A; Cogdill AP; Cooper ZA; Lezcano C; Ferrone CR; Mitra D; Boni A; Newton LP; Liu C; Peng W; Sullivan RJ; Lawrence DP; Hodi FS; Overwijk WW; Lizée G; Murphy GF; Hwu P; Flaherty KT; Fisher DE; Wargo JA
    Clin Cancer Res; 2013 Mar; 19(5):1225-31. PubMed ID: 23307859
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 64. CD160 inhibits activation of human CD4+ T cells through interaction with herpesvirus entry mediator.
    Cai G; Anumanthan A; Brown JA; Greenfield EA; Zhu B; Freeman GJ
    Nat Immunol; 2008 Feb; 9(2):176-85. PubMed ID: 18193050
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Melanoma Treatments: Advances and Mechanisms.
    Marzuka A; Huang L; Theodosakis N; Bosenberg M
    J Cell Physiol; 2015 Nov; 230(11):2626-33. PubMed ID: 25899612
    [TBL] [Abstract][Full Text] [Related]  

  • 66. AurkA inhibitors enhance the effects of B-RAF and MEK inhibitors in melanoma treatment.
    Caputo E; Miceli R; Motti ML; Taté R; Fratangelo F; Botti G; Mozzillo N; Carriero MV; Cavalcanti E; Palmieri G; Ciliberto G; Pirozzi G; Ascierto PA
    J Transl Med; 2014 Jul; 12():216. PubMed ID: 25074438
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [CD160 characterization and its association with disease progression in patients with chronic HIV-1 infection].
    Wang L; Xu X; Feng G; Zhang X; Wang F
    Zhonghua Yi Xue Za Zhi; 2014 May; 94(20):1559-62. PubMed ID: 25146744
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Expansion of CD4 phenotype among CD160 receptor-expressing lymphocytes in murine pregnancy.
    Meggyes M; Szereday L; Jakso P; Bogar B; Bogdan A; Nörenberg J; Miko E; Barakonyi A
    Am J Reprod Immunol; 2017 Dec; 78(6):. PubMed ID: 28921767
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Murine CD160, Ig-like receptor on NK cells and NKT cells, recognizes classical and nonclassical MHC class I and regulates NK cell activation.
    Maeda M; Carpenito C; Russell RC; Dasanjh J; Veinotte LL; Ohta H; Yamamura T; Tan R; Takei F
    J Immunol; 2005 Oct; 175(7):4426-32. PubMed ID: 16177084
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Durable complete responses off all treatment in patients with metastatic malignant melanoma after sequential immunotherapy followed by a finite course of BRAF inhibitor therapy.
    Wyluda EJ; Cheng J; Schell TD; Haley JS; Mallon C; Neves RI; Robertson G; Sivik J; Mackley H; Talamo G; Drabick JJ
    Cancer Biol Ther; 2015; 16(5):662-70. PubMed ID: 25806780
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Soluble CD80 Protein Delays Tumor Growth and Promotes Tumor-Infiltrating Lymphocytes.
    Horn LA; Long TM; Atkinson R; Clements V; Ostrand-Rosenberg S
    Cancer Immunol Res; 2018 Jan; 6(1):59-68. PubMed ID: 29122838
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [mmunotherapy of cutaneous melanoma - update 2022].
    Oláh J
    Magy Onkol; 2022 Jun; 66(2):119-124. PubMed ID: 35724388
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Short-term treatment with multi-drug regimens combining BRAF/MEK-targeted therapy and immunotherapy results in durable responses in
    White MG; Szczepaniak Sloane R; Witt RG; Reuben A; Gaudreau PO; Andrews MC; Feng N; Johnson S; Class CA; Bristow C; Wani K; Hudgens C; Nezi L; Manzo T; De Macedo MP; Hu J; Davis R; Jiang H; Prieto P; Burton E; Hwu P; Tawbi H; Gershenwald J; Lazar AJ; Tetzlaff MT; Overwijk W; Woodman SE; Cooper ZA; Marszalek JR; Davies MA; Heffernan TP; Wargo JA
    Oncoimmunology; 2021; 10(1):1992880. PubMed ID: 34777916
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Comparative efficacy and safety of combination therapies for advanced melanoma: a network meta-analysis.
    An Q; Liu Z
    BMC Cancer; 2019 Jan; 19(1):43. PubMed ID: 30626368
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Targeting oncogenic drivers and the immune system in melanoma.
    McArthur GA; Ribas A
    J Clin Oncol; 2013 Feb; 31(4):499-506. PubMed ID: 23248252
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The CD160, BTLA, LIGHT/HVEM pathway: a bidirectional switch regulating T-cell activation.
    Cai G; Freeman GJ
    Immunol Rev; 2009 May; 229(1):244-58. PubMed ID: 19426226
    [TBL] [Abstract][Full Text] [Related]  

  • 77. CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1.
    Fourcade J; Sun Z; Pagliano O; Guillaume P; Luescher IF; Sander C; Kirkwood JM; Olive D; Kuchroo V; Zarour HM
    Cancer Res; 2012 Feb; 72(4):887-96. PubMed ID: 22205715
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function.
    Boni A; Cogdill AP; Dang P; Udayakumar D; Njauw CN; Sloss CM; Ferrone CR; Flaherty KT; Lawrence DP; Fisher DE; Tsao H; Wargo JA
    Cancer Res; 2010 Jul; 70(13):5213-9. PubMed ID: 20551059
    [TBL] [Abstract][Full Text] [Related]  

  • 79. HLA class I downregulation is associated with enhanced NK-cell killing of melanoma cells with acquired drug resistance to BRAF inhibitors.
    Sottile R; Pangigadde PN; Tan T; Anichini A; Sabbatino F; Trecroci F; Favoino E; Orgiano L; Roberts J; Ferrone S; Kärre K; Colucci F; Carbone E
    Eur J Immunol; 2016 Feb; 46(2):409-19. PubMed ID: 26564811
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Mechanisms of Drug Resistance in Melanoma.
    Winder M; Virós A
    Handb Exp Pharmacol; 2018; 249():91-108. PubMed ID: 28275910
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.